Drug news
NICE recommends Tasigna for Ph+CML
NICE in a final appraisal determination recommends Tasigna (nilotinib) from Novartis for treating chronic or accelerated phase Philadelphia-chromosome-positive CML in adults who are resistant to treatment with standard dose (400mg) Glivec or who are intolerant to Glivec. Novartis will supply the drug at a discount, in line with its patient access scheme.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.